Oppenheimer Downgrades Corcept Therapeutics (CORT) to Perform
Tweet
Share
E-mailGet Alerts CORT Hot Sheet
Price: $22.48 -2.26%
Rating Summary:
7 Buy, 8 Hold, 2 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 3 | Down: 3 | New: 2
Rating Summary:
7 Buy, 8 Hold, 2 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 3 | Down: 3 | New: 2
Join SI Premium – FREE
Oppenheimer downgraded Corcept Therapeutics (NASDAQ: CORT) from Outperform to Perform following Q3 results.
For an analyst ratings summary and ratings history on Corcept Therapeutics click here. For more ratings news on Corcept Therapeutics click here.
Shares of Corcept Therapeutics closed at $2.24 yesterday.
For an analyst ratings summary and ratings history on Corcept Therapeutics click here. For more ratings news on Corcept Therapeutics click here.
Shares of Corcept Therapeutics closed at $2.24 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- JPMorgan Downgrades Monster Beverage (MNST) to Neutral, 'Cost Pressures and Weaker Low-end Consumer'
- Piper Sandler Downgrades Independent Bank Group (IBTX) to Underweight, 'Expectations of Slower NII Recovery'
- Corcept Therapeutics (CORT) Reports Positive Results From Open-Label Portion of Phase 3 GRACE Trial
Create E-mail Alert Related Categories
DowngradesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
